0001225208-18-000838.txt : 20180108 0001225208-18-000838.hdr.sgml : 20180108 20180108164356 ACCESSION NUMBER: 0001225208-18-000838 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180101 FILED AS OF DATE: 20180108 DATE AS OF CHANGE: 20180108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wang Xin Warren CENTRAL INDEX KEY: 0001725283 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 18516891 MAIL ADDRESS: STREET 1: C/O BOSTON SCIENTIFIC CORPORATION STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 3 1 doc3.xml X0206 3 2018-01-01 0 0000885725 BOSTON SCIENTIFIC CORP BSX 0001725283 Wang Xin Warren 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 SVP and Pres, Asia Pacific Common Stock 92531.0000 D Deferred Stock Units 2020-02-23 Common Stock 6346.0000 D Deferred Stock Units 2019-02-24 Common Stock 5276.0000 D Deferred Stock Units 2018-02-28 Common Stock 9337.0000 D Deferred Stock Units 2022-02-28 Common Stock 8146.0000 D Deferred Stock Units 2019-10-27 Common Stock 3052.0000 D Deferred Stock Units 2018-10-29 Common Stock 2545.0000 D Deferred Stock Units 2020-12-01 Common Stock 6075.0000 D Stock Option (Right to Buy) 13.0800 2024-02-24 Common Stock 34500.0000 D Stock Option (Right to Buy) 16.3100 2025-02-23 Common Stock 32003.0000 D Stock Option (Right to Buy) 18.5200 2025-12-01 Common Stock 30637.0000 D Stock Option (Right to Buy) 24.5500 2027-02-28 Common Stock 28860.0000 D Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 23, 2015, which will continue to vest in three remaining installments on the anniversary of the date of grant. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 24, 2014, which will continue to vest in two remaining installments on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on February 28, 2013, which will continue to vest in one remaining installment on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 27, 2015, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on October 27, 2014, which will continue to vest in two remaining installments on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on October 29, 2013, which will continue to vest in one remaining installment on the anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant. This amount represents the unvested portion of DSUs awarded on December 1, 2015, which will continue to vest in three remaining installments on the anniversary of the date of grant. Grant to the reporting person of an option to purchase a 34,500 shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a 32,003 shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a 30,637 shares of common stock vesting in four equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a 28,860 shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. wangpoa.txt /s/ Vance R. Brown, Attorney-in-fact 2018-01-08 EX-24 2 wangpoa.txt POWER OF ATTORNEY Know all by these present that the undersigned hereby constitutes and appoints each of Desiree Ralls-Morrison, Vance R. Brown, Jeff Mann, Ashley E. McGrane and Mai-KhoiNguyen-Thanh signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of Boston Scientific Corporation (the "Company"), Forms 3, 4 and 5, and amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer and/or director of the Company, Forms 144 in accordance with Rule 144 of the Securities Exchange Act of 1933, as amended and the rules and regulations thereunder; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities Act of 1933, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of December, 2017. /s/ Xin Warren Wang ________________ Xin Warren Wang